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The 2013 “Vaccine and Drug Ontology Studies” (VDOS 2013) international workshop series focuses on vaccine- and
drug-related ontology modeling and applications. Drugs and vaccines have contributed to dramatic improvements
in public health worldwide. Over the last decade, tremendous efforts have been made in the biomedical ontology
community to ontologically represent various areas associated with vaccines and drugs – extending existing clinical
terminology systems such as SNOMED, RxNorm, NDF-RT, and MedDRA, as well as developing new models such as
Vaccine Ontology. The VDOS workshop series provides a platform for discussing innovative solutions as well as the
challenges in the development and applications of biomedical ontologies for representing and analyzing drugs and
vaccines, their administration, host immune responses, adverse events, and other related topics. The six full-length
papers included in this thematic issue focuses on three main areas: (i) ontology development and representation,
(ii) ontology mapping, maintaining and auditing, and (iii) ontology applications.Introduction and background
Drugs and vaccines have been critical to prevent and
treat human and animal diseases. Work in both (drugs
and vaccines) areas is closely related - from preclinical
research and development to manufacturing, clinical trials,
government approval and regulation, and post-licensure
usage surveillance and monitoring. Many drug and vaccine
related ontologies have already been or are being developed
for different use cases and applications. The 2013 “Vaccine
and Drug Ontology Studies” workshop (VDOS 2013) work-
shop series aims to become an international forum for
researchers to identify, propose, and discuss solutions for
important research problems in ontology representation
and analysis of vaccine and drug formation and prepar-
ation, administration, function mechanisms, and induced
host immune responses. The immune responses can be
positive responses for prevention and/or treatment of a
disease, or can be negative responses, i.e., adverse events.
This workshop aimed to support the deeper understand-
ing of vaccine and drug mechanisms and effects.
VDOS 2013 was held on July 7, 2013, at Montreal, Qc,
Canada. This workshop was part of the fourth Inter-
national Conference on Biomedical Ontology (ICBO 2013).* Correspondence: cui.tao@uth.tmc.edu
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unless otherwise stated.The workshop attracted interest from many international
attendees, including paper presenters, senior academic and
government scientists, postdoctoral fellows, and graduate
students. After a rigorous peer review process (all submis-
sions have been reviewed by at least three independent
reviewers), six full-length papers and three short-length
papers were accepted for proceeding paper publications
and oral presentations in the workshop. After one add-
itional round of independent peer reviewing by the
workshop co-organizers and the journal editors, the
selected six full-length papers were extended and accepted
for publication in the current issue of the Journal of
Biomedical Semantics (JBMS).
The VDOS-2013 workshop is the 2nd in this series.
The first workshop of the series was organized as the
“Vaccine and Drug Ontology in the Study of Mechanism
and Effect” workshop (VDOSME 2012) [1] on July 21,
2012, at Graz, Germany, as part of the third International
Conference on Biomedical Ontology (ICBO 2012). For
this year, the name has been changed to “Vaccine and
Drug Ontology Studies (VDOS)” to reflect the expansion
in the scope to more than just mechanism and effect.
The workshop series also covers vaccine and drug-related
clinical data representation and analysis, including clinic-
ally reported vaccine and drug adverse events.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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The six papers selected for this thematic issue are extended
versions of the original full-length papers presented at
the VDOS 2013 [2-7]. These papers cover a wide range
of topics including ontology development and repre-
sentation, ontology mapping, maintaining and auditing,
and ontology applications.
In the area of ontology development and representation,
Lin and He introduced their Ontology of Genetic Suscep-
tibility Factors (OGSF) for representing the susceptibility
factors for post vaccination events using a formal onto-
logical mechanism [2]. OGSF is aligned with the Basic
Formal Ontology (BFO). This paper ontologically defines
two core OGSF terms ‘genetic susceptibility’ and ‘genetic
susceptibility factor’ and the design pattern for represent-
ing genetic susceptibility to a vaccine adverse event. Two
use cases related to the genetic susceptibility to adverse
events following vaccination of an influenza vaccine or
smallpox vaccine were studied using the OGSF ontology.
Hanna et al built the Drug Ontology (DrOn) to model
drug information for comparative-effectiveness research
[3]. DrOn is represented in OWL2 and covers drug infor-
mation derived from three different sources (RxNorm,
ChEBI, and PRO). Although DrOn was originally designed
for comparative-effectiveness research studies, it can also
service many other use cases in the biomedical domain.
Marcos and He [4] developed the Ontology of Vaccine
Adverse Events (OVAE). OVAE was built as an extension
of the Vaccine Ontology (VO) and the Ontology of Adverse
Events (OAE). It represents and classifies the adverse events
recorded in package insert documents of commercial vac-
cines licensed by the USA Food and Drug Administration
(FDA). OVAE will be very useful in supporting rational
VAE prevention and treatment and benefits public health.
In the area of ontology mapping, Winnenburg, et al.
tried to map the terms in (Anatomical Therapeutic
Chemical (ATC) and Medical Subject Headings (MeSH)
through the Unified Medical Language System (UMLS)
[5]. Both lexical-based and instance-based mapping were
performed, which yielded hundreds of new mappings
between the two terminology systems. The alignment
between ATC and MeSH can be critical for drug evalu-
ation and safety studies as well as for pharmacogenetic
research. On one hand, MEDLINE literature is indexed
using MeSH. On the other hand, adverse drug events are
usually analyzed in reference to ATC. In order to integrate
drug information from these different sources, a reliable
alignment between ATC and MeSH is very much desired.
In the area of ontology applications, Doulaverakis et al.
present a semantic framework to discover drug-drug and
drug-disease interactions [6]. They use SKOS to represent
the semantics of the medical classification for drug rele-
vant information derived from ICD-10, Unique Ingredi-
ent Identifier (UNII), ATC, and the International VirusTaxonomy (IVT). Rule-based reasoning approaches were
then used to identify drug recommendations. Zhang et al.
introduce a novel approach that combines ontologies and
network analysis technologies for identifying new associa-
tions among vaccines, genes, and diseases [7]. The authors
leverage data extracted from MEDLINE and represented
this information using Resource Description Framework
(RDF). This RDF graph can then be viewed as a network
to perform network analysis.
Workshop presentations and discussions
In the workshop, the six full-length papers described above
were orally presented. In addition, three short papers were
accepted for short oral presentations. Zhu et al. introduces
their work on building a drug and drug class network
derived from multiple drug terminological resources, such
as ATC, National Drug File Reference Terminology (NDF-
RT), RxNorm, and Structured Product Label (SPL) [8]. He
et al. investigated how to audit the redundancies caused
by importing top-level ontologies [9]. More specifically,
they studied the redundancies in Drug Discovery Investi-
gations ontology (DDI) when importing BFO. Hall et al.
introduces their software that supports extracting new
drug information from drug structured product labels
(SPL) to update the DrOn [10].
During the discussion session, we discussed two main
areas – (a) mapping between different drug models (6
papers), and (b) adverse events detection and analysis
(3 papers). The major focuses on drug ontologies them-
selves (including models that contribute greatly in this
area), their goals, and the challenges in aligning them,
show that some of the preparatory work still needs to
be done to continue the research into adverse events. A
number of different approaches to drug mapping were
discussed – lexical, ingredient based, using chemical
structures and by exploiting networks (e.g. via the UMLS).
While each provided their unique benefits, there was
concurrence on the need for using more than one
method to improve the quality of mapping. Furthermore,
these papers also demonstrated the need for enhancing
the definitions (logical and textual) of the terms and the
relations both for improved human understanding as well
as for better integration between them. The two papers
focusing on adverse event detection and analysis also
highlighted some of the gaps and shed light on areas
for further ontology development efforts. These studies
also demonstrated promising usages and advantages of
ontology in standardizing, integrating, and analyzing
adverse event data.
Overall, the VDOS 2013 workshop provided an ideal
platform for ontology researchers and users to present
and discuss the progresses and issues in the development
and applications of ontologies related to vaccines and
drugs. Positive feedbacks were obtained.
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